Cardio-oncology & other

A Simple Clinical Risk Score to Improve Prediction of Anthracycline-Induced Cardiotoxicity

JACC CardioOncolPublished Retrospective cohort study

Authors' conclusion

HFA-ICOS score effectively stratifies baseline risk, while the RE-ACT score provides additional post-treatment prognostic value.

Study context

Population
Adult cancer patients with baseline left ventricular ejection fraction (LVEF) ≥50% treated with anthracyclinesexternal validation n = 819
Participants
2,612 patients
Exposure
RE-ACT score vs Heart Failure Association-International Cardio-Oncology Society (HFA-ICOS) score
Outcome
Cardiotoxicity (LVEF decrease >10 percentage points to <50% or HF)
Follow-up
1 year
Methodological detailsrisk score development and validation, cross-validation, external validation cohort
  • Risk score development and validation
  • Cross-validation
  • External validation cohort

Main finding

As reported in the abstract

Discrimination for cardiotoxicity (AUC)
GroupAUC
HFA-ICOS0.76 (95% CI: 0.67-0.86)
RE-ACT0.83 (95% CI: 0.74-0.93)
Combined0.87 (95% CI: 0.80-0.95)

AUC

HFA-ICOS0.76 (95% CI: 0.67-0.86)
RE-ACT0.83 (95% CI: 0.74-0.93)
Combined0.87 (95% CI: 0.80-0.95)
  • Combined vs HFA-ICOS: P < 0.001 — derivation cohort

Observational data: associations, not effects.

Further findings

OutcomeHR (95% CI)
Cardiotoxicity by HFA-ICOS risk category vs low risk · first 2 yearsModerate riskvs Low risk1.44 (1.02–2.06)
Cardiotoxicity by HFA-ICOS risk category vs low risk · first 2 yearsHigh riskvs Low risk1.84 (1.36–2.50)
RE-ACT AUC in validation cohort · 1 year
0.88 (95% CI: 0.80-0.95) · AUC

Cumulative incidence of cardiotoxicity · 12 months

Cumulative incidence
8.3% (95% CI: 7.1%-9.1%)
Additional events through 2 years
5

Original publication

A Simple Clinical Risk Score to Improve Prediction of Anthracycline-Induced Cardiotoxicity. JACC CardioOncol. Published August 2026. doi:10.1016/j.jaccao.2026.06.005

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.